Their findings light on the reverse correlation between the expression levels of ST3GAL3 and the dosage of cisplatin used in various cell lines and claim that by targeting ST3GAL3, chemoresistance of cisplatin can be prevented the relapse of ovarian cancer [64]. The gene discussed is ST3GAL3; the disease is ovarian carcinoma.